Study: FDA should warn consumers about chemical in weight loss supplements
Several weight loss and fitness supplements contain the chemical BMPEA, a stimulant similar to amphetamine, according to a new study.
Several weight loss and fitness supplements contain the chemical BMPEA, a stimulant similar to amphetamine, according to a new study.
The study, published in the April 7 online issue of Drug Testing and Analysis, found that the stimulant BMPEA, labeled as Acacia rigidula, “was present at quantities such that consumers following recommended maximum daily servings would consume a maximum of 93.7 mg of BMPEA per day.”
Related: FDA issues new labeling indications for testosterone replacement therapy
“Consumers of Acacia rigidula supplements may be exposed to pharmacological dosages of an amphetamine isomer that lacks evidence of safety in humans. FDA should immediately warn consumers about BMPEA and take aggressive enforcement action to eliminate BMPEA in dietary supplements,” the researchers from Harvard Medical School in Boston, Mass., and other US universities wrote in the article.
BMPEA was first discovered in a handful of dietary supplements analyzed by FDA in 2013. Over a year after FDA reported its findings, the researchers analyzed 21 different brands of Acacia rigidula dietary supplements to determine if BMPEA had been removed.
Related: FDA updates Chantix label to include possible alcohol interaction
The researchers did not name the specific supplements they analyzed.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
